• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Advertisement

New Delhi Feb. 6 Ranbaxy Laboratories Ltd has finalised a financial advisor for its bid for the generic business of Merck KgaA. Mr Malvinder Mohan Singh, CEO and MD, refusing to name the advisor or the private equity firms the company was in discussion with, said, "We are interested in Merck's business, and we will only consider acquiring it at a fair and right price."

Mr Singh believes that emerging markets, by sheer volume, would be of great importance to Ranbaxy's strategic plans for 2007.

The German company's sale price has been evaluated by analysts at $5.2 billion, and Ranbaxy and Cipla are the two Indian companies who have evinced interest in it. However, other Indian pharmaceutical majors are also believed to be talking to private equity firms to strengthen their bids.

More Stories on : Mergers & Acquisitions | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Lakshmi Machine in modernisation mode

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line